You are leaving Medscape Education
Cancel Continue
Log in to save activities Your saved activities will show here so that you can easily access them whenever you're ready. Log in here CME & Education Log in to keep track of your credits.
 

 

CME / ABIM MOC / CE

Are Implantable Cardioverter Defibrillators Still Needed for Primary Prevention?

  • Authors: News Author: Steve Stiles; CME Author: Charles P. Vega, MD
  • CME / ABIM MOC / CE Released: 10/7/2022
  • Valid for credit through: 10/7/2023
Start Activity

  • Credits Available

    Physicians - maximum of 0.25 AMA PRA Category 1 Credit(s)™

    ABIM Diplomates - maximum of 0.25 ABIM MOC points

    Nurses - 0.25 ANCC Contact Hour(s) (0.25 contact hours are in the area of pharmacology)

    Pharmacists - 0.25 Knowledge-based ACPE (0.025 CEUs)

    Physician Assistant - 0.25 AAPA hour(s) of Category I credit

    IPCE - 0.25 Interprofessional Continuing Education (IPCE) credit

    You Are Eligible For

    • Letter of Completion
    • ABIM MOC points

Target Audience and Goal Statement

This activity is intended for primary care physicians, cardiologists, nurses and nurse practitioners, pharmacists, physician assistants, and other members of the healthcare team who treat and manage patients with heart failure with reduced ejection fraction.

The goal of this activity is for learners to be better able to evaluate outcomes of guideline-directed medical therapy for heart failure with reduced ejection fraction among patients with an implantable cardioverter-defibrillator or cardiac resynchronization therapy-defibrillator.

Upon completion of this activity, participants will:

  • Assess the efficacy of all 4 guideline-based treatments for heart failure with reduced ejection fraction
  • Evaluate outcomes of guideline-directed medical therapy for heart failure with reduced ejection fraction among patients with implantable cardioverter-defibrillator or cardiac resynchronization therapy-defibrillator
  • Outline implications for the healthcare team


Disclosures

Medscape, LLC requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated. Others involved in the planning of this activity have no relevant financial relationships.


News Author

  • Steve Stiles

    News Editor, theheart.org | Medscape Cardiology

    Disclosures

    Steve Stiles has no relevant financial relationships.

CME Author

  • Charles P. Vega, MD

    Health Sciences Clinical Professor of Family Medicine
    University of California, Irvine School of Medicine

    Disclosures

    Charles P. Vega, MD, has the following relevant financial relationships:
    Consultant or advisor for: GlaxoSmithKline; Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Editor/Nurse Planner

  • Leigh Schmidt, MSN, RN, CNE, CHCP

    Associate Director, Accreditation and Compliance, Medscape, LLC

    Disclosures

    Leigh Schmidt, MSN, RN, CNE, CHCP, has no relevant financial relationships.

Compliance Reviewer

  • Yaisanet Oyola, MD

    Associate Director, Accreditation and Compliance, Medscape, LLC

    Disclosures

    Yaisanet Oyola, MD, has no relevant financial relationships.

Peer Reviewer

This activity has been peer reviewed and the reviewer has disclosed no relevant financial relationships.


Accreditation Statements



In support of improving patient care, Medscape, LLC is jointly accredited with commendation by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

This activity was planned by and for the healthcare team, and learners will receive 0.25 Interprofessional Continuing Education (IPCE) credit for learning and change.

    For Physicians

  • Medscape, LLC designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™ . Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.25 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

    Contact This Provider

    For Nurses

  • Awarded 0.25 contact hour(s) of continuing nursing education for RNs and APNs; 0.25 contact hours are in the area of pharmacology.

    Contact This Provider

    For Pharmacists

  • Medscape, LLC designates this continuing education activity for 0.25 contact hour(s) (0.025 CEUs) (Universal Activity Number JA0007105-0000-22-290-H01-P).

    Contact This Provider

  • For Physician Assistants

    Medscape, LLC has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 0.25 AAPA Category 1 CME credits. Approval is valid until 10/7/2023. PAs should only claim credit commensurate with the extent of their participation.

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]


Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the activity online during the valid credit period that is noted on the title page. To receive AMA PRA Category 1 Credit™, you must receive a minimum score of 70% on the post-test.

Follow these steps to earn CME/CE credit*:

  1. Read about the target audience, learning objectives, and author disclosures.
  2. Study the educational content online or print it out.
  3. Online, choose the best answer to each test question. To receive a certificate, you must receive a passing score as designated at the top of the test. We encourage you to complete the Activity Evaluation to provide feedback for future programming.

You may now view or print the certificate from your CME/CE Tracker. You may print the certificate, but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period, you can print out the tally as well as the certificates from the CME/CE Tracker.

*The credit that you receive is based on your user profile.

CME / ABIM MOC / CE

Are Implantable Cardioverter Defibrillators Still Needed for Primary Prevention?

Authors: News Author: Steve Stiles; CME Author: Charles P. Vega, MDFaculty and Disclosures

CME / ABIM MOC / CE Released: 10/7/2022

Valid for credit through: 10/7/2023

processing....

Clinical Context

The management of heart failure with reduced ejection fraction (HFrEF) has come a long way in the past 2 decades, with treatment with a combination of 4 classes of drugs improving patient outcomes. A study using modeling based on the results of randomized controlled trials found that the number needed to treat with the combination of angiotensin receptor neprilysin inhibitors (ARNI), beta-blockers, sodium-glucose cotransporter 2 inhibitors (SGLT2i), and aldosterone antagonists over the course of 2 years to prevent 1 additional case of mortality in cases of HFrEF was just 3.9.[1]

The authors of this review provided an analysis of the efficacy of different drug classes for HFrEF against mortality, as follows:

 Agent

 Relative risk reduction in mortality 

 ARNI

 16%

 Beta-blocker

 34%

 Aldosterone antagonist

 30%

 SGLT2i

 17%

Does guideline-directed medical therapy (GDMT) for HFrEF have the same effect in improving mortality among patients who received an implantable cardioverter-defibrillator (ICD)? The current study provides an answer.

Study Synopsis and Perspective

Contemporary guidelines highly recommend that patients with HFrEF receive all 4 drug classes that together have shown clinical clout, including improved survival, in major randomized trials.[2]

Although many such patients do not receive all 4 drug classes, the more drug classes that are prescribed to those with primary prevention implantable defibrillators (ICD), the better their odds of survival, a new analysis suggests.

The cohort study of almost 5000 patients with HFrEF and such devices saw their all-cause mortality risk improve stepwise with each additional prescription they were given toward the full quadruple drug combo at the core of modern HFrEF GDMT.

That inverse relation between risk and number of GDMT medications held whether patients had solo-ICD or defibrillating cardiac resynchronization therapy (CRT-D) implants, independent of device implantation year and comorbidities and regardless of HFrEF etiology.

"If anybody had doubts about really pushing forward as much of these guideline-directed medical therapies as the patient tolerates, these data confirm that by doing so, we definitely do better than with 2 medications or one medication," Samir Saba, MD, from the University of Pittsburgh Medical Center, Pennsylvania, told theheart.org | Medscape Cardiology.

The analysis begs an old and challenging question: Do primary prevention ICDs confer clinically important survival gains over those provided by increasingly life-preserving recommended HFrEF medical therapy?

Given the study's incremental survival bumps with each added GDMT medication, "one ought to consider whether ICD therapy can still have an impact on overall survival in this population," proposes a report published online July 27 in JACC Clinical Electrophysiology, with Dr Saba as senior author and Mehak Dhande, MD, also from University of Pittsburgh Medical Center, as lead author.[3]

In the adjusted analysis, the 2-year risk for death from any cause in patients with HFrEF with primary prevention devices fell 36% in those with ICDs and 30% in those with CRT-D devices for each added prescribed GDMT drug, from none up to either 3 or 4 such agents (P<.001 in both cases).

Only so much can be made of nonrandomized study results, Dr Saba observed in an interview. But they are enough to justify asking whether primary prevention ICDs are "still valuable" in HFrEF, given today's GDMT. 

Both defibrillators and the 4 core drug therapies boost survival in such cases, so, for now, at least, the findings could reassure clinicians as they consider whether to [recommend] a primary prevention ICD when there might be reasons not to, as long there is full GDMT on board.

Recently announced North American guidelines defining an HFrEF quadruple regimen prefer, beyond a beta blocker, MRA, and SGLT2 inhibitor, that the selected RAS inhibitor be sacubitril/valsartan with ACEi or angiotensin-receptor blockers (ARBs) as a substitute, if needed.[4]

Nearly identical European guidelines on HFrEF quad therapy, unveiled last year, include but do not necessarily prefer sacubitril/valsartan over ACEi as the RAS inhibitor of choice.[5]

GDMT a Moving Target

Primary prevention defibrillators entered practice at a time when expected background GDMT consisted of beta blockers and either ACEi or ARBs, the current report notes. In practice, many patients receive the devices without both drug classes optimally on board. Moreover, many who otherwise meet guidelines for such ICDs will not tolerate the kind of maximally tolerated GDMT used in the major primary prevention device trials.

Yet current guidelines give such devices a class I recommendation, based on the highest level of evidence, in patients with HFrEF who remain symptomatic despite quad GDMT, observed Gregg C. Fonarow, MD, from the University of California Los Angeles Medical Center.

The current analysis "further reinforces the importance of providing all 4 foundational GDMTs" to all eligible patients with HFrEF without contraindications who can tolerate them, he told theheart.org | Medscape Cardiology. Such quad therapy, he said, "is associated with incremental 1-year survival advantages" in patients with primary prevention devices. And in the major trials, "there were reductions in sudden deaths, as well as progressive heart failure deaths."

But the current study also suggests that in practice, "very few patients can actually get to all 4 drugs on GDMT," said Roderick Tung, MD, from the University of Arizona College of Medicine, Phoenix. Optimized GDMT in randomized trials probably represents the best-case scenario, he told theheart.org | Medscape Cardiology

And it asserts that "the more GDMT you're on, the better you do," he said. "But does that obviate the need for an ICD? I think that's not clear," in part because of potential confounding in the analysis. For example, patients who can receive all 4 agents tend to be less sick than those who cannot.

Indeed, the major primary prevention ICD trials usually excluded the sickest patients with the most comorbidities, Dr Saba observed, which raises issues about their relevance to clinical practice. But his group's study controlled for many potential confounders by adjusting for, among other things, Elixhauser comorbidity score, ejection fraction, type of cardiomyopathy, and year of device implantation.

GDMT Coverage in the Real World

The analysis of patients with HFrEF involved 3210 patients with ICD-only implants and 1762 with CRT-D devices for primary prevention at a major medical center from 2010 to 2021. Of the total, 5% had not been prescribed any of the 4 GDMT agents, 20% had been prescribed only 1, 52% were prescribed 2, and 23% were prescribed 3 or 4. Only 113 patients had been prescribed SGLT2 inhibitors, which have only recently been indicated for HFrEF.

Adjusted hazard ratios for death from any cause at 2 years for each added GDMT drug (P < .001 in each case), were:

  • 0.64 (95% confidence interval [CI], 0.56-0.74) for ICD recipients
  • 0.70 (95% CI, 0.58-0.86) for those with a CRT-D device
  • 0.70 (95% CI, 0.60-0.81) for those with ischemic cardiomyopathy
  • 0.61 (95% CI, 0.51-0.73) for patients with nonischemic disease

The results "raise questions rather than answers," Dr Saba said. "At some point, someone will need to take patients who are optimized on their heart failure medications and then randomize them to defibrillator versus no defibrillator to see whether there is still an additive impact."

Current best evidence suggests that primary prevention ICDs in patients with guideline-based indications confer benefits that far outweigh any risks. Still, he said, a background of modern GDMT could potentially "optimize" such trials by attenuating mortality from heart failure progression and thereby expanding the proportion of deaths that are arrhythmic, "which the defibrillator can prevent."

Dr Saba discloses receiving research support from Boston Scientific and Abbott and serving on advisory boards for Medtronic and Boston Scientific. The other authors have disclosed no relevant financial relationships. Dr Tung has disclosed receiving speaker fees from Abbott and Boston Scientific. Dr Fonarow has reported receiving personal fees from Abbott, Amgen, AstraZeneca, Bayer, Cytokinetics, Edwards, Janssen, Medtronic, Merck, and Novartis.

Study Highlights

  • The study was conducted as a retrospective chart review of patients with HFrEF who received ICD or CRT-D as primary prevention at 1 university-based hospital system in the US. Patients were seen between 2010 and 2021. 
  • The primary study endpoint was all-cause mortality at 2 years after device implantation. The main study variable was the number of GDMT agents (between 0 and 4) prescribed to patients. 
  • 4972 patients provided data for study analysis. 65% received ICD, and 35% received CRT-D.
  • The mean age of patients was 67 years, and the majority were male. More than 85% of patients were White.
  • 13% of patients died within 2 years of device implantation. Among patients who received an ICD there was a stepwise decline in the rate of mortality as higher degrees of GDMT were applied, from a rate of 26% among patients with 0 GDMT to 7% among patients receiving 3 to 4 GDMT. The respective decline was even more precipitous in the CRT-D cohort (from 30% to 8%).
  • The addition of each additional GDMT drug was associated with a hazard ratio (HR) of 0.66 (95% CI, 0.59-0.74) for death.
  • The benefit of higher rates of GDMT was similar regardless of CRT or CRT-D, and it was also not significantly affected by a history of ischemic vs nonischemic cardiomyopathy.
  • Specifically, the use of either an SGLT2i or ARNI was associated with an HR of death of 0.60 (95% CI, 0.41-0.88) at 2 years.
  • 52% of deaths were cardiac in nature, 13% of all deaths were attributed to arrhythmia, and all of these deaths involved ventricular arrhythmia specifically.

Clinical Implications

  • A previous study examined the efficacy of GDMT for HFrEF, with efficacy against mortality ranging from 16% to 34% for individual agents. Combined, these agents reduced mortality by 73%, resulting in a number needed to treat of less than 4.
  • The current study demonstrates the mortality benefit of GDMT in patients with ICD or CRT-D for primary prevention, regardless of the etiology of cardiomyopathy. There was a 34% lower risk of mortality with each GDMT drug added.
  • Implications for the healthcare team: The healthcare team should provide education on and emphasize adherence to the maximum number of GDMT drugs tolerated in cases of HFrEF, regardless of ICD status.

Earn Credit